LONDON, ONTARIO--(Marketwire - Oct. 5, 2011) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that a scientific abstract about its lead oncology compound, COTI-2, has been accepted for presentation at the upcoming scientific conference, Discovery on Target: Emerging Targets for the Kinase Inhibitor Pipeline. The presentation entitled COTI-2: A highly effective and selective modulator of Akt/Akt2 protein levels and phospho-activation for the treatment of susceptible human cancers will be presented by Dr. Wayne Danter, COTI's CEO and CSO. This conference is being held November 2-4, 2011 in Boston, MA.

"The acceptance of our abstract indicates an eagerness on the part of the oncology community to learn more about our promising COTI-2 program," said Dr. Danter. "This upcoming presentation will afford us the opportunity to showcase to key influencers from many partnering organizations the science behind COTI-2, including the most recent data confirming that Akt/Akt2 are key cellular targets for COTI-2. It also serves as further validation for the ability of our proprietary artificial intelligence system, CHEMSAS®, to generate important drug candidates."

COTI-2 is the most advanced compound in COTI's drug development pipeline and is the first to have been discovered by the CHEMSAS® process. COTI-2's specific cellular targeting, low toxicity, and proven efficacy support a potentially dramatic change in the treatment of cancers that over express Akt/Akt2. Over expression of Akt/Akt2 is common in a broad range of human cancers, including ovarian, endometrial, pancreatic, breast, colorectal and lung. The percent of tumors with active Akt/Akt2 range from 20% to 100% depending on the cancer type.